# Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

> **NCT02504489** · PHASE3 · COMPLETED · sponsor: **BeyondSpring Pharmaceuticals Inc.** · enrollment: 559 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Docetaxel + Plinabulin (DP)
- **DRUG:** Docetaxel (D)

## Key facts

- **NCT ID:** NCT02504489
- **Lead sponsor:** BeyondSpring Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2021-03-23
- **Final completion:** 2021-05-23
- **Target enrollment:** 559 (ACTUAL)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504489, "Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02504489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*